Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: A study of 45 cases

Esther Oliva, Nathanael F. Pinheiro, Niall M. Heney, Donald S. Kaufman, William U. Shipley, Carol Gurski, Beverly Spicer, Gladell P. Paner, Allen M. Gown, Mahul Amin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Muscle invasive urothelial carcinoma has been treated with cystectomy ± adjuvant therapy. Recently, a bladder-sparing protocol has been offered to selected patients closely followed with surveillance biopsies. In this setting, radiation-induced changes (RAD-Ch) may be very difficult to distinguish from carcinoma in situ, and failing to recognize them may lead to overtreatment. We ascertained the role of immunohistochemistry using cytokeratin (CK) 20, p53, and CD44s in bladder biopsies from 28 patients with a history of bladder radiation and 17 with carcinoma in situ without radiation. Negative or weak multifocal nuclear p53 staining was seen in 24 of 28 RAD-Ch cases, whereas strong and diffuse nuclear p53 staining was found in 8 of 17 carcinoma in situ cases and moderate and focal to multifocal in 3. CK20 showed strong cytoplasmic staining of only umbrella cells in 22 of 28 RAD-Ch cases. In contrast, 11 of 17 carcinomas in situ showed diffuse and strong CK20 positivity and 5 moderate and focal to multifocal positivity. All carcinomas in situ with weak or no p53 showed significant CK20 staining except 1. CD44s displayed diffuse membranous positivity in 7 of 17 RAD-Ch cases and up to mid-third in 8. Only 1 of 17 carcinomas in situ had diffuse membranous CD44s staining. Diffuse and significant CK20 expression was seen in most carcinomas in situ. Strong and diffuse p53 expression was only seen in carcinoma in situ (∼50%), whereas diffuse CD44s staining was typically only seen in RAD-Ch. Our data suggest that a CK20- p53- CD44a panel proves to be very helpful (CK20 more reliable than p53 or CD44s) in the diagnosis of RAD-Ch.

Original languageEnglish (US)
Pages (from-to)860-866
Number of pages7
JournalHuman pathology
Volume44
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Carcinoma in Situ
Urinary Bladder
Differential Diagnosis
Immunohistochemistry
Radiation
Staining and Labeling
Keratin-20
Biopsy
Cystectomy
Carcinoma
Muscles

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder : A study of 45 cases. / Oliva, Esther; Pinheiro, Nathanael F.; Heney, Niall M.; Kaufman, Donald S.; Shipley, William U.; Gurski, Carol; Spicer, Beverly; Paner, Gladell P.; Gown, Allen M.; Amin, Mahul.

In: Human pathology, Vol. 44, No. 5, 01.05.2013, p. 860-866.

Research output: Contribution to journalArticle

Oliva, Esther ; Pinheiro, Nathanael F. ; Heney, Niall M. ; Kaufman, Donald S. ; Shipley, William U. ; Gurski, Carol ; Spicer, Beverly ; Paner, Gladell P. ; Gown, Allen M. ; Amin, Mahul. / Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder : A study of 45 cases. In: Human pathology. 2013 ; Vol. 44, No. 5. pp. 860-866.
@article{9f345dc1b8674386b86547b19d040e7c,
title = "Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: A study of 45 cases",
abstract = "Muscle invasive urothelial carcinoma has been treated with cystectomy ± adjuvant therapy. Recently, a bladder-sparing protocol has been offered to selected patients closely followed with surveillance biopsies. In this setting, radiation-induced changes (RAD-Ch) may be very difficult to distinguish from carcinoma in situ, and failing to recognize them may lead to overtreatment. We ascertained the role of immunohistochemistry using cytokeratin (CK) 20, p53, and CD44s in bladder biopsies from 28 patients with a history of bladder radiation and 17 with carcinoma in situ without radiation. Negative or weak multifocal nuclear p53 staining was seen in 24 of 28 RAD-Ch cases, whereas strong and diffuse nuclear p53 staining was found in 8 of 17 carcinoma in situ cases and moderate and focal to multifocal in 3. CK20 showed strong cytoplasmic staining of only umbrella cells in 22 of 28 RAD-Ch cases. In contrast, 11 of 17 carcinomas in situ showed diffuse and strong CK20 positivity and 5 moderate and focal to multifocal positivity. All carcinomas in situ with weak or no p53 showed significant CK20 staining except 1. CD44s displayed diffuse membranous positivity in 7 of 17 RAD-Ch cases and up to mid-third in 8. Only 1 of 17 carcinomas in situ had diffuse membranous CD44s staining. Diffuse and significant CK20 expression was seen in most carcinomas in situ. Strong and diffuse p53 expression was only seen in carcinoma in situ (∼50{\%}), whereas diffuse CD44s staining was typically only seen in RAD-Ch. Our data suggest that a CK20- p53- CD44a panel proves to be very helpful (CK20 more reliable than p53 or CD44s) in the diagnosis of RAD-Ch.",
author = "Esther Oliva and Pinheiro, {Nathanael F.} and Heney, {Niall M.} and Kaufman, {Donald S.} and Shipley, {William U.} and Carol Gurski and Beverly Spicer and Paner, {Gladell P.} and Gown, {Allen M.} and Mahul Amin",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.humpath.2012.08.011",
language = "English (US)",
volume = "44",
pages = "860--866",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder

T2 - A study of 45 cases

AU - Oliva, Esther

AU - Pinheiro, Nathanael F.

AU - Heney, Niall M.

AU - Kaufman, Donald S.

AU - Shipley, William U.

AU - Gurski, Carol

AU - Spicer, Beverly

AU - Paner, Gladell P.

AU - Gown, Allen M.

AU - Amin, Mahul

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Muscle invasive urothelial carcinoma has been treated with cystectomy ± adjuvant therapy. Recently, a bladder-sparing protocol has been offered to selected patients closely followed with surveillance biopsies. In this setting, radiation-induced changes (RAD-Ch) may be very difficult to distinguish from carcinoma in situ, and failing to recognize them may lead to overtreatment. We ascertained the role of immunohistochemistry using cytokeratin (CK) 20, p53, and CD44s in bladder biopsies from 28 patients with a history of bladder radiation and 17 with carcinoma in situ without radiation. Negative or weak multifocal nuclear p53 staining was seen in 24 of 28 RAD-Ch cases, whereas strong and diffuse nuclear p53 staining was found in 8 of 17 carcinoma in situ cases and moderate and focal to multifocal in 3. CK20 showed strong cytoplasmic staining of only umbrella cells in 22 of 28 RAD-Ch cases. In contrast, 11 of 17 carcinomas in situ showed diffuse and strong CK20 positivity and 5 moderate and focal to multifocal positivity. All carcinomas in situ with weak or no p53 showed significant CK20 staining except 1. CD44s displayed diffuse membranous positivity in 7 of 17 RAD-Ch cases and up to mid-third in 8. Only 1 of 17 carcinomas in situ had diffuse membranous CD44s staining. Diffuse and significant CK20 expression was seen in most carcinomas in situ. Strong and diffuse p53 expression was only seen in carcinoma in situ (∼50%), whereas diffuse CD44s staining was typically only seen in RAD-Ch. Our data suggest that a CK20- p53- CD44a panel proves to be very helpful (CK20 more reliable than p53 or CD44s) in the diagnosis of RAD-Ch.

AB - Muscle invasive urothelial carcinoma has been treated with cystectomy ± adjuvant therapy. Recently, a bladder-sparing protocol has been offered to selected patients closely followed with surveillance biopsies. In this setting, radiation-induced changes (RAD-Ch) may be very difficult to distinguish from carcinoma in situ, and failing to recognize them may lead to overtreatment. We ascertained the role of immunohistochemistry using cytokeratin (CK) 20, p53, and CD44s in bladder biopsies from 28 patients with a history of bladder radiation and 17 with carcinoma in situ without radiation. Negative or weak multifocal nuclear p53 staining was seen in 24 of 28 RAD-Ch cases, whereas strong and diffuse nuclear p53 staining was found in 8 of 17 carcinoma in situ cases and moderate and focal to multifocal in 3. CK20 showed strong cytoplasmic staining of only umbrella cells in 22 of 28 RAD-Ch cases. In contrast, 11 of 17 carcinomas in situ showed diffuse and strong CK20 positivity and 5 moderate and focal to multifocal positivity. All carcinomas in situ with weak or no p53 showed significant CK20 staining except 1. CD44s displayed diffuse membranous positivity in 7 of 17 RAD-Ch cases and up to mid-third in 8. Only 1 of 17 carcinomas in situ had diffuse membranous CD44s staining. Diffuse and significant CK20 expression was seen in most carcinomas in situ. Strong and diffuse p53 expression was only seen in carcinoma in situ (∼50%), whereas diffuse CD44s staining was typically only seen in RAD-Ch. Our data suggest that a CK20- p53- CD44a panel proves to be very helpful (CK20 more reliable than p53 or CD44s) in the diagnosis of RAD-Ch.

UR - http://www.scopus.com/inward/record.url?scp=84876484267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876484267&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.08.011

DO - 10.1016/j.humpath.2012.08.011

M3 - Article

C2 - 23199526

AN - SCOPUS:84876484267

VL - 44

SP - 860

EP - 866

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 5

ER -